NuCana Q2 Earnings: Recent Updates Bode Poorly, Not Worth The Risk (NASDAQ:NCNA)

Intestine microvilli close up 3d render. Gut microbiome and digestive system of human

Oleksandra Troian/iStock via Getty Images

Topline summary

NuCana PLC (NASDAQ:NCNA) is in a class of biotechs attempting to make better versions of tried-and-true chemotherapeutics, tackling areas of major unmet need like colorectal cancer. However, they have faced a bevy of issues, including the

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *